Althera received approval of its own development product AL-320 (rosuvastatin/ezetimibe tablets) in 2017 in major European markets. Additionally AL-110 (metformin XR/rosuvastatin tablets) is currently in registration phase in Europe and other markets. AL-310 (atorvastatin/ezetimibe) product is in the final development stage and is expected to be filed in major markets in 2017.
Additionally several projects are in early stage of development.
We also undertake extensive licensing and acquisition activities to bring specialty products to market that make significant impact on the lives of patients we aim to serve.
Below is our portfolio development tracker as of 2nd quarter 2017.